FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes

In patients with T2D treated with a combination of metformin/pioglitazone/exenatide (triple therapy), we observed reduced total and bioactive plasma FGF21 levels and a relative increase in the proportion of circulating bioactive FGF21 compared with that in patients treated with metformin and sequent...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of physiology: endocrinology and metabolism Vol. 323; no. 2; pp. E123 - E132
Main Authors Samms, Ricardo J., Cheng, Christine C., Fourcaudot, Marcel, Heikkinen, Sami, Khattab, Ahmed, Adams, John, Cersosimo, Eugenio, Triplitt, Curtis, Puckett, Curtis, Tsintzas, Kostas, Adams, Andrew. C., Abdul-Ghani, Muhammad A., DeFronzo, Ralph A., Norton, Luke
Format Journal Article
LanguageEnglish
Published United States American Physiological Society 01.08.2022
SeriesTranslational Physiology
Subjects
Antidiabetics
Baseline studies
Beta cells
Biological activity
Blood Glucose - metabolism
Carbohydrates
Combination therapy
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - drug therapy
Exenatide
Fibroblast Growth Factors
Glipizide
Glucose
Glucose tolerance
Glycated Hemoglobin - metabolism
Growth factors
Humans
Hypoglycemic Agents - therapeutic use
Ingestion
Insulin
Insulin Resistance
Metabolism
Metformin
Metformin - therapeutic use
Patients
Peptides
Pioglitazone
Sensitivity analysis
Therapy
Thiazolidinediones
Venoms
glucose
insulin
triple therapy
diabetes
FGF21
Online AccessGet full text

Cover

Abstract In patients with T2D treated with a combination of metformin/pioglitazone/exenatide (triple therapy), we observed reduced total and bioactive plasma FGF21 levels and a relative increase in the proportion of circulating bioactive FGF21 compared with that in patients treated with metformin and sequential addition of glipizide and basal insulin glargine (conventional therapy). These data suggest that FGF21 may contribute, at least in part, to the glycemic benefits observed following combination therapy in patients with T2D. Fibroblast growth factor 21 (FGF21) is increased acutely by carbohydrate ingestion and is elevated in patients with type 2 diabetes (T2D). However, the physiological significance of increased FGF21 in humans remains largely unknown. We examined whether FGF21 contributed to the metabolic improvements observed following treatment of patients with T2D with either triple (metformin/pioglitazone/exenatide) or conventional (metformin/insulin/glipizide) therapy for 3 yr. Forty-six patients with T2D were randomized to receive either triple or conventional therapy to maintain HbA1c < 6.5%. A 2-h 75-g oral glucose tolerance test (OGTT) was performed at baseline and following 3 years of treatment to assess glucose tolerance, insulin sensitivity, and β-cell function. Plasma total and bioactive FGF21 levels were quantitated before and during the OGTT at both visits. Patients in both treatment arms experienced significant improvements in glucose control, but insulin sensitivity and β-cell function were markedly increased after triple therapy. At baseline, FGF21 levels were regulated acutely during the OGTT in both groups. After treatment, fasting total and bioactive FGF21 levels were significantly reduced in patients receiving triple therapy, but there was a relative increase in the proportion of bioactive FGF21 compared with that observed in conventionally treated subjects. Relative to baseline studies, triple therapy treatment also significantly modified FGF21 levels in response to a glucose load. These changes in circulating FGF21 were correlated with markers of improved glucose control and insulin sensitivity. Alterations in the plasma FGF21 profile may contribute to the beneficial metabolic effects of pioglitazone and exenatide in human patients with T2D. NEW & NOTEWORTHY In patients with T2D treated with a combination of metformin/pioglitazone/exenatide (triple therapy), we observed reduced total and bioactive plasma FGF21 levels and a relative increase in the proportion of circulating bioactive FGF21 compared with that in patients treated with metformin and sequential addition of glipizide and basal insulin glargine (conventional therapy). These data suggest that FGF21 may contribute, at least in part, to the glycemic benefits observed following combination therapy in patients with T2D.
AbstractList Fibroblast growth factor 21 (FGF21) is increased acutely by carbohydrate ingestion and is elevated in patients with type 2 diabetes (T2D). However, the physiological significance of increased FGF21 in humans remains largely unknown. We examined whether FGF21 contributed to the metabolic improvements observed following treatment of patients with T2D with either triple (metformin/pioglitazone/exenatide) or conventional (metformin/insulin/glipizide) therapy for 3 yr. Forty-six patients with T2D were randomized to receive either triple or conventional therapy to maintain HbA1c < 6.5%. A 2-h 75-g oral glucose tolerance test (OGTT) was performed at baseline and following 3 years of treatment to assess glucose tolerance, insulin sensitivity, and β-cell function. Plasma total and bioactive FGF21 levels were quantitated before and during the OGTT at both visits. Patients in both treatment arms experienced significant improvements in glucose control, but insulin sensitivity and β-cell function were markedly increased after triple therapy. At baseline, FGF21 levels were regulated acutely during the OGTT in both groups. After treatment, fasting total and bioactive FGF21 levels were significantly reduced in patients receiving triple therapy, but there was a relative increase in the proportion of bioactive FGF21 compared with that observed in conventionally treated subjects. Relative to baseline studies, triple therapy treatment also significantly modified FGF21 levels in response to a glucose load. These changes in circulating FGF21 were correlated with markers of improved glucose control and insulin sensitivity. Alterations in the plasma FGF21 profile may contribute to the beneficial metabolic effects of pioglitazone and exenatide in human patients with T2D.
Fibroblast growth factor 21 (FGF21) is increased acutely by carbohydrate ingestion and is elevated in patients with type 2 diabetes (T2D). However, the physiological significance of increased FGF21 in humans remains largely unknown. We examined whether FGF21 contributed to the metabolic improvements observed following treatment of patients with T2D with either triple (metformin/pioglitazone/exenatide) or conventional (metformin/insulin/glipizide) therapy for 3 yr. Forty-six patients with T2D were randomized to receive either triple or conventional therapy to maintain HbA1c < 6.5%. A 2-h 75-g oral glucose tolerance test (OGTT) was performed at baseline and following 3 years of treatment to assess glucose tolerance, insulin sensitivity, and β-cell function. Plasma total and bioactive FGF21 levels were quantitated before and during the OGTT at both visits. Patients in both treatment arms experienced significant improvements in glucose control, but insulin sensitivity and β-cell function were markedly increased after triple therapy. At baseline, FGF21 levels were regulated acutely during the OGTT in both groups. After treatment, fasting total and bioactive FGF21 levels were significantly reduced in patients receiving triple therapy, but there was a relative increase in the proportion of bioactive FGF21 compared with that observed in conventionally treated subjects. Relative to baseline studies, triple therapy treatment also significantly modified FGF21 levels in response to a glucose load. These changes in circulating FGF21 were correlated with markers of improved glucose control and insulin sensitivity. Alterations in the plasma FGF21 profile may contribute to the beneficial metabolic effects of pioglitazone and exenatide in human patients with T2D.NEW & NOTEWORTHY In patients with T2D treated with a combination of metformin/pioglitazone/exenatide (triple therapy), we observed reduced total and bioactive plasma FGF21 levels and a relative increase in the proportion of circulating bioactive FGF21 compared with that in patients treated with metformin and sequential addition of glipizide and basal insulin glargine (conventional therapy). These data suggest that FGF21 may contribute, at least in part, to the glycemic benefits observed following combination therapy in patients with T2D.Fibroblast growth factor 21 (FGF21) is increased acutely by carbohydrate ingestion and is elevated in patients with type 2 diabetes (T2D). However, the physiological significance of increased FGF21 in humans remains largely unknown. We examined whether FGF21 contributed to the metabolic improvements observed following treatment of patients with T2D with either triple (metformin/pioglitazone/exenatide) or conventional (metformin/insulin/glipizide) therapy for 3 yr. Forty-six patients with T2D were randomized to receive either triple or conventional therapy to maintain HbA1c < 6.5%. A 2-h 75-g oral glucose tolerance test (OGTT) was performed at baseline and following 3 years of treatment to assess glucose tolerance, insulin sensitivity, and β-cell function. Plasma total and bioactive FGF21 levels were quantitated before and during the OGTT at both visits. Patients in both treatment arms experienced significant improvements in glucose control, but insulin sensitivity and β-cell function were markedly increased after triple therapy. At baseline, FGF21 levels were regulated acutely during the OGTT in both groups. After treatment, fasting total and bioactive FGF21 levels were significantly reduced in patients receiving triple therapy, but there was a relative increase in the proportion of bioactive FGF21 compared with that observed in conventionally treated subjects. Relative to baseline studies, triple therapy treatment also significantly modified FGF21 levels in response to a glucose load. These changes in circulating FGF21 were correlated with markers of improved glucose control and insulin sensitivity. Alterations in the plasma FGF21 profile may contribute to the beneficial metabolic effects of pioglitazone and exenatide in human patients with T2D.NEW & NOTEWORTHY In patients with T2D treated with a combination of metformin/pioglitazone/exenatide (triple therapy), we observed reduced total and bioactive plasma FGF21 levels and a relative increase in the proportion of circulating bioactive FGF21 compared with that in patients treated with metformin and sequential addition of glipizide and basal insulin glargine (conventional therapy). These data suggest that FGF21 may contribute, at least in part, to the glycemic benefits observed following combination therapy in patients with T2D.
Fibroblast growth factor 21 (FGF21) is increased acutely by carbohydrate ingestion and is elevated in patients with type 2 diabetes (T2D). However, the physiological significance of increased FGF21 in humans remains largely unknown. We examined whether FGF21 contributed to the metabolic improvements observed following treatment of patients with T2D with either triple (metformin/pioglitazone/exenatide) or conventional (metformin/insulin/glipizide) therapy for 3 yr. Forty-six patients with T2D were randomized to receive either triple or conventional therapy to maintain HbA1c < 6.5%. A 2-h 75-g oral glucose tolerance test (OGTT) was performed at baseline and following 3 years of treatment to assess glucose tolerance, insulin sensitivity, and β-cell function. Plasma total and bioactive FGF21 levels were quantitated before and during the OGTT at both visits. Patients in both treatment arms experienced significant improvements in glucose control, but insulin sensitivity and β-cell function were markedly increased after triple therapy. At baseline, FGF21 levels were regulated acutely during the OGTT in both groups. After treatment, fasting total and bioactive FGF21 levels were significantly reduced in patients receiving triple therapy, but there was a relative increase in the proportion of bioactive FGF21 compared with that observed in conventionally treated subjects. Relative to baseline studies, triple therapy treatment also significantly modified FGF21 levels in response to a glucose load. These changes in circulating FGF21 were correlated with markers of improved glucose control and insulin sensitivity. Alterations in the plasma FGF21 profile may contribute to the beneficial metabolic effects of pioglitazone and exenatide in human patients with T2D. NEW & NOTEWORTHY In patients with T2D treated with a combination of metformin/pioglitazone/exenatide (triple therapy), we observed reduced total and bioactive plasma FGF21 levels and a relative increase in the proportion of circulating bioactive FGF21 compared with that in patients treated with metformin and sequential addition of glipizide and basal insulin glargine (conventional therapy). These data suggest that FGF21 may contribute, at least in part, to the glycemic benefits observed following combination therapy in patients with T2D.
Fibroblast growth factor 21 (FGF21) is increased acutely by carbohydrate ingestion and is elevated in patients with type 2 diabetes (T2D). However, the physiological significance of increased FGF21 in humans remains largely unknown. We examined whether FGF21 contributed to the metabolic improvements observed following treatment of patients with T2D with either triple (metformin/pioglitazone/exenatide) or conventional (metformin/insulin/glipizide) therapy for 3 yr. Forty-six patients with T2D were randomized to receive either triple or conventional therapy to maintain HbA1c < 6.5%. A 2-h 75-g oral glucose tolerance test (OGTT) was performed at baseline and following 3 years of treatment to assess glucose tolerance, insulin sensitivity, and β-cell function. Plasma total and bioactive FGF21 levels were quantitated before and during the OGTT at both visits. Patients in both treatment arms experienced significant improvements in glucose control, but insulin sensitivity and β-cell function were markedly increased after triple therapy. At baseline, FGF21 levels were regulated acutely during the OGTT in both groups. After treatment, fasting total and bioactive FGF21 levels were significantly reduced in patients receiving triple therapy, but there was a relative increase in the proportion of bioactive FGF21 compared with that observed in conventionally treated subjects. Relative to baseline studies, triple therapy treatment also significantly modified FGF21 levels in response to a glucose load. These changes in circulating FGF21 were correlated with markers of improved glucose control and insulin sensitivity. Alterations in the plasma FGF21 profile may contribute to the beneficial metabolic effects of pioglitazone and exenatide in human patients with T2D. In patients with T2D treated with a combination of metformin/pioglitazone/exenatide (triple therapy), we observed reduced total and bioactive plasma FGF21 levels and a relative increase in the proportion of circulating bioactive FGF21 compared with that in patients treated with metformin and sequential addition of glipizide and basal insulin glargine (conventional therapy). These data suggest that FGF21 may contribute, at least in part, to the glycemic benefits observed following combination therapy in patients with T2D.
In patients with T2D treated with a combination of metformin/pioglitazone/exenatide (triple therapy), we observed reduced total and bioactive plasma FGF21 levels and a relative increase in the proportion of circulating bioactive FGF21 compared with that in patients treated with metformin and sequential addition of glipizide and basal insulin glargine (conventional therapy). These data suggest that FGF21 may contribute, at least in part, to the glycemic benefits observed following combination therapy in patients with T2D. Fibroblast growth factor 21 (FGF21) is increased acutely by carbohydrate ingestion and is elevated in patients with type 2 diabetes (T2D). However, the physiological significance of increased FGF21 in humans remains largely unknown. We examined whether FGF21 contributed to the metabolic improvements observed following treatment of patients with T2D with either triple (metformin/pioglitazone/exenatide) or conventional (metformin/insulin/glipizide) therapy for 3 yr. Forty-six patients with T2D were randomized to receive either triple or conventional therapy to maintain HbA1c < 6.5%. A 2-h 75-g oral glucose tolerance test (OGTT) was performed at baseline and following 3 years of treatment to assess glucose tolerance, insulin sensitivity, and β-cell function. Plasma total and bioactive FGF21 levels were quantitated before and during the OGTT at both visits. Patients in both treatment arms experienced significant improvements in glucose control, but insulin sensitivity and β-cell function were markedly increased after triple therapy. At baseline, FGF21 levels were regulated acutely during the OGTT in both groups. After treatment, fasting total and bioactive FGF21 levels were significantly reduced in patients receiving triple therapy, but there was a relative increase in the proportion of bioactive FGF21 compared with that observed in conventionally treated subjects. Relative to baseline studies, triple therapy treatment also significantly modified FGF21 levels in response to a glucose load. These changes in circulating FGF21 were correlated with markers of improved glucose control and insulin sensitivity. Alterations in the plasma FGF21 profile may contribute to the beneficial metabolic effects of pioglitazone and exenatide in human patients with T2D. NEW & NOTEWORTHY In patients with T2D treated with a combination of metformin/pioglitazone/exenatide (triple therapy), we observed reduced total and bioactive plasma FGF21 levels and a relative increase in the proportion of circulating bioactive FGF21 compared with that in patients treated with metformin and sequential addition of glipizide and basal insulin glargine (conventional therapy). These data suggest that FGF21 may contribute, at least in part, to the glycemic benefits observed following combination therapy in patients with T2D.
Author Cersosimo, Eugenio
Samms, Ricardo J.
Khattab, Ahmed
Heikkinen, Sami
Triplitt, Curtis
Tsintzas, Kostas
Adams, Andrew. C.
Cheng, Christine C.
Abdul-Ghani, Muhammad A.
Adams, John
Norton, Luke
DeFronzo, Ralph A.
Fourcaudot, Marcel
Puckett, Curtis
Author_xml – sequence: 1
  givenname: Ricardo J.
  orcidid: 0000-0001-9138-3091
  surname: Samms
  fullname: Samms, Ricardo J.
  organization: Eli Lilly and Company, Indianapolis, Indiana
– sequence: 2
  givenname: Christine C.
  surname: Cheng
  fullname: Cheng, Christine C.
  organization: Eli Lilly and Company, Indianapolis, Indiana
– sequence: 3
  givenname: Marcel
  surname: Fourcaudot
  fullname: Fourcaudot, Marcel
  organization: Diabetes Division, University of Texas Health San Antonio, San Antonio, Texas
– sequence: 4
  givenname: Sami
  surname: Heikkinen
  fullname: Heikkinen, Sami
  organization: Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland
– sequence: 5
  givenname: Ahmed
  surname: Khattab
  fullname: Khattab, Ahmed
  organization: Diabetes Division, University of Texas Health San Antonio, San Antonio, Texas
– sequence: 6
  givenname: John
  surname: Adams
  fullname: Adams, John
  organization: Diabetes Division, University of Texas Health San Antonio, San Antonio, Texas
– sequence: 7
  givenname: Eugenio
  surname: Cersosimo
  fullname: Cersosimo, Eugenio
  organization: Diabetes Division, University of Texas Health San Antonio, San Antonio, Texas
– sequence: 8
  givenname: Curtis
  surname: Triplitt
  fullname: Triplitt, Curtis
  organization: Diabetes Division, University of Texas Health San Antonio, San Antonio, Texas
– sequence: 9
  givenname: Curtis
  surname: Puckett
  fullname: Puckett, Curtis
  organization: Diabetes Division, University of Texas Health San Antonio, San Antonio, Texas
– sequence: 10
  givenname: Kostas
  orcidid: 0000-0002-3405-5769
  surname: Tsintzas
  fullname: Tsintzas, Kostas
  organization: School of Life Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham, United Kingdom
– sequence: 11
  givenname: Andrew. C.
  surname: Adams
  fullname: Adams, Andrew. C.
  organization: Eli Lilly and Company, Indianapolis, Indiana
– sequence: 12
  givenname: Muhammad A.
  surname: Abdul-Ghani
  fullname: Abdul-Ghani, Muhammad A.
  organization: Diabetes Division, University of Texas Health San Antonio, San Antonio, Texas
– sequence: 13
  givenname: Ralph A.
  surname: DeFronzo
  fullname: DeFronzo, Ralph A.
  organization: Eli Lilly and Company, Indianapolis, Indiana
– sequence: 14
  givenname: Luke
  orcidid: 0000-0002-0231-5722
  surname: Norton
  fullname: Norton, Luke
  organization: Diabetes Division, University of Texas Health San Antonio, San Antonio, Texas
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35723225$$D View this record in MEDLINE/PubMed
BookMark eNp9ks9u1DAQxi1URLeFF-CALHHhksV_N8kFCVVsQarEBc6WHU-6XiV2sJ3C8gw8NM52i6AH5IOlmd98_sYzF-jMBw8IvaRkTalkb_V-Am_DmhAiyZoRxp6gVUmwikopz9CK0JZXtBHtObpIaV-4Wgr2DJ1zWTPOmFyhX9vrLaO4Cz5HZ-YMCeeAR8jahMF12I1TDHcwgs8JQ4m4DBabQ6kYjfM6u-Bx3kHU0wF_d3mH4QcsYQtYe4snF24Hl_XPYh07j6eSOmod2XyYADNsnTZQnn6OnvZ6SPDidF-ir9sPX64-Vjefrz9dvb-pOsFJrmrBNBPQ18JuOtr3ZNOYtjRkSGNq0xC-nLruOtC2Z1paYgQB3VouxALzS_TuXneazQi2K4aiHtQU3ajjQQXt1L8Z73bqNtyplrVUUF4E3pwEYvg2Q8pqdKmDYdAewpwU29RNzVvCNwV9_Qjdhzn60l6h2gLJRtJCvfrb0R8rD4MqQHMPdDGkFKFXZRLH3y8G3aAoUctOqNNOqONOqGUnSil7VPqg_p-i3x6TvyM
CitedBy_id crossref_primary_10_1111_eci_14334
crossref_primary_10_1210_clinem_dgad583
crossref_primary_10_1186_s43088_024_00571_0
crossref_primary_10_3389_fmed_2024_1459752
crossref_primary_10_3389_fendo_2024_1358311
crossref_primary_10_1016_j_dsx_2023_102720
crossref_primary_10_1186_s12902_023_01523_y
crossref_primary_10_1038_s41574_023_00898_1
Cites_doi 10.1016/j.fob.2013.12.001
10.1111/dom.12652
10.2337/db13-0645
10.1042/BJ20151085
10.1016/j.febslet.2009.07.053
10.2337/db05-1200
10.1016/j.cell.2011.11.062
10.1007/s12020-020-02186-8
10.1210/en.2010-1262
10.1016/j.cmet.2019.01.004
10.1038/jhh.2012.52
10.2337/db10-0193
10.2337/db16-1167
10.2337/diacare.22.9.1462
10.1172/JCI23606
10.1055/s-2007-985148
10.2337/db18-0155
10.1038/ijo.2014.76
10.1016/j.cmet.2016.02.001
10.1371/journal.pone.0209060
10.1016/j.molmet.2013.05.005
10.1210/en.2006-1168
10.7717/peerj.12755
10.1016/j.molmet.2014.09.008
10.1155/2019/5163245
10.1210/jc.2017-00047
10.2147/DMSO.S291350
10.1016/j.jhep.2010.05.018
10.1016/j.cmet.2007.05.002
10.1007/s00125-011-2317-z
10.2337/db17-0318
10.1152/ajpendo.00551.2006
10.1111/dom.12417
10.1177/1479164118825376
10.1210/jc.2017-01257
10.1053/j.gastro.2010.04.054
10.1046/j.1432-1327.1998.2540650.x
10.1371/journal.pone.0148252
10.1530/EJE-09-0335
10.1016/j.cmet.2018.03.001
10.1016/j.diabet.2016.04.005
10.1371/journal.pone.0151269
10.1073/pnas.1200797109
10.1016/j.cmet.2013.08.005
10.1016/j.cmet.2007.05.003
10.1136/bmjdrc-2019-000741
10.2337/db14-0541
10.1210/en.2014-2001
10.2337/dc09-0684
10.1016/j.molmet.2018.10.011
10.1371/journal.pone.0015534
10.1124/mol.108.044826
ContentType Journal Article
Copyright Copyright American Physiological Society Aug 2022
Copyright © 2022 the American Physiological Society. 2022 American Physiological Society
Copyright_xml – notice: Copyright American Physiological Society Aug 2022
– notice: Copyright © 2022 the American Physiological Society. 2022 American Physiological Society
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7TS
7U7
C1K
7X8
5PM
DOI 10.1152/ajpendo.00050.2022
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Calcium & Calcified Tissue Abstracts
Physical Education Index
Toxicology Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Toxicology Abstracts
Calcium & Calcified Tissue Abstracts
Physical Education Index
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList Toxicology Abstracts
MEDLINE - Academic

MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Anatomy & Physiology
DocumentTitleAlternate COMBINATION THERAPY REGULATES FGF21 LEVELS
EISSN 1522-1555
EndPage E132
ExternalDocumentID PMC9291413
35723225
10_1152_ajpendo_00050_2022
Genre Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NIDDK NIH HHS
  grantid: R01 DK129676
– fundername: NIDDK NIH HHS
  grantid: R01 DK128247
– fundername: ;
– fundername: ;
  grantid: DK129676
– fundername: ;
  grantid: DK128247
GroupedDBID ---
23M
2WC
39C
4.4
53G
5GY
5VS
6J9
AAYXX
ABJNI
ACPRK
ADBBV
AENEX
AFRAH
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BKKCC
BKOMP
BTFSW
CITATION
E3Z
EBS
EMOBN
F5P
GX1
H13
ITBOX
KQ8
OK1
P2P
P6G
PQQKQ
RAP
RHI
RPL
RPRKH
TR2
W8F
WH7
WOQ
XSW
YSK
CGR
CUY
CVF
ECM
EIF
NPM
7QP
7TS
7U7
C1K
7X8
5PM
ID FETCH-LOGICAL-c430t-742a24ef74d6c1ff068b9723b08b7b803030377cceadf2a5d0b40ea9d344f0683
ISSN 0193-1849
1522-1555
IngestDate Thu Aug 21 18:42:26 EDT 2025
Fri Jul 11 16:21:19 EDT 2025
Mon Jun 30 10:36:15 EDT 2025
Mon Jul 21 05:55:44 EDT 2025
Thu Apr 24 23:02:27 EDT 2025
Tue Jul 01 03:40:32 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords glucose
insulin
triple therapy
diabetes
FGF21
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c430t-742a24ef74d6c1ff068b9723b08b7b803030377cceadf2a5d0b40ea9d344f0683
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ORCID 0000-0002-3405-5769
0000-0002-0231-5722
0000-0001-9138-3091
OpenAccessLink https://nottingham-repository.worktribe.com/file/8955760/1/FGF21%20contributes%20to%20metabolic%20improvements%20elicited%20by%20combination%20therapy%20with%20exenatide%20and%20pioglitazone%20in%20patients%20with%20type%202%20diabetes
PMID 35723225
PQID 2697395851
PQPubID 48583
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_9291413
proquest_miscellaneous_2678739036
proquest_journals_2697395851
pubmed_primary_35723225
crossref_citationtrail_10_1152_ajpendo_00050_2022
crossref_primary_10_1152_ajpendo_00050_2022
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-08-01
PublicationDateYYYYMMDD 2022-08-01
PublicationDate_xml – month: 08
  year: 2022
  text: 2022-08-01
  day: 01
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Bethesda
– name: Rockville, MD
PublicationSeriesTitle Translational Physiology
PublicationTitle American journal of physiology: endocrinology and metabolism
PublicationTitleAlternate Am J Physiol Endocrinol Metab
PublicationYear 2022
Publisher American Physiological Society
Publisher_xml – name: American Physiological Society
References B20
B21
B22
B23
B24
B25
B26
B27
B28
B29
B30
B31
B32
B33
B34
B35
B36
B37
B38
B39
B1
B2
B3
B4
B5
B6
B7
B8
B9
B40
B41
B42
B43
B44
B45
B46
B47
B48
B49
B50
B51
B52
B10
B11
B12
B13
B14
B15
B16
B17
B18
B19
References_xml – ident: B19
  doi: 10.1016/j.fob.2013.12.001
– ident: B39
  doi: 10.1111/dom.12652
– ident: B42
  doi: 10.2337/db13-0645
– ident: B20
  doi: 10.1042/BJ20151085
– ident: B9
  doi: 10.1016/j.febslet.2009.07.053
– ident: B31
  doi: 10.2337/db05-1200
– ident: B41
  doi: 10.1016/j.cell.2011.11.062
– ident: B28
  doi: 10.1007/s12020-020-02186-8
– ident: B18
  doi: 10.1210/en.2010-1262
– ident: B3
  doi: 10.1016/j.cmet.2019.01.004
– ident: B35
  doi: 10.1038/jhh.2012.52
– ident: B17
  doi: 10.2337/db10-0193
– ident: B25
  doi: 10.2337/db16-1167
– ident: B24
  doi: 10.2337/diacare.22.9.1462
– ident: B1
  doi: 10.1172/JCI23606
– ident: B12
  doi: 10.1055/s-2007-985148
– ident: B50
  doi: 10.2337/db18-0155
– ident: B14
  doi: 10.1038/ijo.2014.76
– ident: B7
  doi: 10.1016/j.cmet.2016.02.001
– ident: B32
  doi: 10.1371/journal.pone.0209060
– ident: B46
  doi: 10.1016/j.molmet.2013.05.005
– ident: B2
  doi: 10.1210/en.2006-1168
– ident: B40
  doi: 10.7717/peerj.12755
– ident: B11
  doi: 10.1016/j.molmet.2014.09.008
– ident: B34
  doi: 10.1155/2019/5163245
– ident: B30
  doi: 10.1210/jc.2017-00047
– ident: B29
  doi: 10.2147/DMSO.S291350
– ident: B16
  doi: 10.1016/j.jhep.2010.05.018
– ident: B45
  doi: 10.1016/j.cmet.2007.05.002
– ident: B48
  doi: 10.1007/s00125-011-2317-z
– ident: B26
  doi: 10.2337/db17-0318
– ident: B38
  doi: 10.1152/ajpendo.00551.2006
– ident: B23
  doi: 10.1111/dom.12417
– ident: B36
  doi: 10.1177/1479164118825376
– ident: B10
  doi: 10.1210/jc.2017-01257
– ident: B15
  doi: 10.1053/j.gastro.2010.04.054
– ident: B21
  doi: 10.1046/j.1432-1327.1998.2540650.x
– ident: B51
  doi: 10.1371/journal.pone.0148252
– ident: B47
  doi: 10.1530/EJE-09-0335
– ident: B37
  doi: 10.1016/j.cmet.2018.03.001
– ident: B49
  doi: 10.1016/j.diabet.2016.04.005
– ident: B52
  doi: 10.1371/journal.pone.0151269
– ident: B43
  doi: 10.1073/pnas.1200797109
– ident: B6
  doi: 10.1016/j.cmet.2013.08.005
– ident: B8
  doi: 10.1016/j.cmet.2007.05.003
– ident: B27
  doi: 10.1136/bmjdrc-2019-000741
– ident: B4
  doi: 10.2337/db14-0541
– ident: B5
  doi: 10.1210/en.2014-2001
– ident: B13
  doi: 10.2337/dc09-0684
– ident: B22
  doi: 10.1016/j.molmet.2018.10.011
– ident: B33
  doi: 10.1371/journal.pone.0015534
– ident: B44
  doi: 10.1124/mol.108.044826
SSID ssj0007542
Score 2.4384346
Snippet In patients with T2D treated with a combination of metformin/pioglitazone/exenatide (triple therapy), we observed reduced total and bioactive plasma FGF21...
Fibroblast growth factor 21 (FGF21) is increased acutely by carbohydrate ingestion and is elevated in patients with type 2 diabetes (T2D). However, the...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage E123
SubjectTerms Antidiabetics
Baseline studies
Beta cells
Biological activity
Blood Glucose - metabolism
Carbohydrates
Combination therapy
Diabetes
Diabetes mellitus (non-insulin dependent)
Diabetes Mellitus, Type 2 - drug therapy
Exenatide
Fibroblast Growth Factors
Glipizide
Glucose
Glucose tolerance
Glycated Hemoglobin - metabolism
Growth factors
Humans
Hypoglycemic Agents - therapeutic use
Ingestion
Insulin
Insulin Resistance
Metabolism
Metformin
Metformin - therapeutic use
Patients
Peptides
Pioglitazone
Sensitivity analysis
Therapy
Thiazolidinediones
Venoms
Title FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes
URI https://www.ncbi.nlm.nih.gov/pubmed/35723225
https://www.proquest.com/docview/2697395851
https://www.proquest.com/docview/2678739036
https://pubmed.ncbi.nlm.nih.gov/PMC9291413
Volume 323
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBAvE2xcOgYyEuIFpSTO_XGaWirYhpBaqW9RnLgsjCbTlkp0v4H_yd_gHNtxXTpNgCpVVeImVs4Xn4vP-Q4hb0BFclD8rlPEaQQOSsHhlUpKhwdBngTccwvZtO_0LBpPg4-zcNbr_bKylpYtHxQ3t9aV_I9U4RjIFatk_0Gy5qJwAH6DfOEbJAzffyXj0YcR81S2ObatUmwNC9GCYJG7upIBA6GK2AQckeYl2JswF3CIlehVAdZKBWTFD4GHS7WncFk1X5HD-6ZR1CKag_X61uCtbeWabSCLl0KGUFRpDDYDqssG1qt6zQDVTVszGmLQJ1_oOBBc66ps1jtYx-dCLVGKGgENZRPsHeFuRL4EZ1uXIhXCJJGMRXVxAaNVzDdfVHbMA9zlLuOutcoMUEl0U5eA1nmudrQ09R1wYdWaLPQKD5cDIyq0VYCvap411pm1oA89dWpb04TIXJt_w07FzUDy6Axwqmu92uUSnH3ORtOTk2wynE3ukfsM_BlstfHpy5rWHtsQq7p-Nd-uuitk77fvsGlBbblFf2b3WubS5BHZ1X4OPVKgfUx6ot4j-0eArmaxom-peaarPfLgVCd47JOfEtLUgjRtG2ogTW1I0w7SlK-oBWmqIU0RptRAmgLKqA1pWtW0g7Qai5CmjHaQfkKmo-HkeOzohiFOEfhu68QBy1kg5nFQRoU3n7tRwrGrHncTHvME9Bl84rgoYPmcszwsXR64Ik9LPwhwsP-U7NRw_-eEhsz3Xc7KCJY4rAVNo4iVhYfVVKwU86RPvE4IWaHZ9LGpy_dMetUhy7TgMim4DAXXJ-_Mfy4Vl8ydow872Wb6bb3OWJTizjq4SX3y2pwGjYDbfHktmiWOASXsp2Ca9skzBQVzOz-ExwEqvE_iDZCYAcg2v3mmrs4l6zz4UR5YvAd3T-sFebh-YQ_JTnu1FC_BbG_5Kwn5392q-XA
linkProvider Colorado Alliance of Research Libraries
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=FGF21+contributes+to+metabolic+improvements+elicited+by+combination+therapy+with+exenatide+and+pioglitazone+in+patients+with+type+2+diabetes&rft.jtitle=American+journal+of+physiology%3A+endocrinology+and+metabolism&rft.au=Samms%2C+Ricardo+J&rft.au=Cheng%2C+Christine+C&rft.au=Fourcaudot%2C+Marcel&rft.au=Heikkinen%2C+Sami&rft.date=2022-08-01&rft.pub=American+Physiological+Society&rft.issn=0193-1849&rft.eissn=1522-1555&rft.volume=323&rft.issue=2&rft.spage=E123&rft_id=info:doi/10.1152%2Fajpendo.00050.2022&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0193-1849&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0193-1849&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0193-1849&client=summon